Resolution of proximal tubular dysfunction after liver transplantation in ATP8B1 deficiency: A case report Authors: Angela Marino, Nathalie Godefroid, Catherine De Magnée, Xavier Stephenne Published: 2026 ABSTRACT AbstractProgressive familial intrahepatic cholestasis type 1 (PFIC1), caused by ATP8B1 deficiency, is a multisystem disorder with extrahepatic manifestations; however, renal involvement has rarely been described. We report a child with genetically confirmed PFIC1 who underwent living donor liver transplantation (LT) for progressive liver disease. Before transplantation, serum creatinine was normal, but a Fanconi‐like proximal tubular dysfunction was characterized by elevated urinary β2‐microglobulin, proteinuria, phosphaturia, hypercalciuria, and metabolic acidosis requiring bicarbonate supplementation. Following transplantation, these abnormalities rapidly resolved, supporting the hypothesis of reversible cholestasis‐associated tubular injury. This case identifies proximal tubular dysfunction as an underrecognized, potentially reversible manifestation of severe, prolonged cholestasis in PFIC1 and supports systematic evaluation of tubular markers before transplantation.Keywords: Fanconi syndrome, progressive familial intrahepatic cholestasis, renal tubulopathy INTRODUCTION Progressive familial intrahepatic cholestasis (PFIC) comprises inherited bile‐secretion disorders causing progressive cholestatic liver disease from early childhood. PFIC Type 1 is caused by pathogenic variants in ATP8B1, encoding the phospholipid flippase FIC1, which maintains membrane phospholipid asymmetry in epithelial cells. 1 In contrast to other PFIC subtypes, ATP8B1 is expressed in multiple extrahepatic tissues, including the intestine, pancreas, and inner ear, causing chronic diarrhea, pancreatic dysfunction, growth impairment, and sensorineural hearing loss. 2 , 3 Although liver transplantation (LT) effectively corrects hepatic cholestasis, it does not restore the underlying epithelial defect, and extrahepatic manifestations may persist or worsen after transplantation. 2 We report a child with genetically confirmed PFIC1 who developed proximal tubular dysfunction before LT that rapidly resolved afterward, supporting a reversible mechanism related to severe and prolonged cholestasis. CASE REPORT A boy born to consanguineous parents was diagnosed with PFIC1 and underwent living donor LT at 10 years of age. Cholestatic jaundice was present from early infancy and progressed to severe, longstanding cholestasis with debilitating pruritus throughout childhood despite long‐term supportive therapy, including ursodeoxycholic acid, rifampicin, and fat‐soluble vitamin supplementation. The disease followed a progressive course, leading to cirrhosis with clinical and radiological evidence of portal hypertension, resulting in LT. During pre‐transplant evaluation, renal function was systematically assessed. Serum creatinine was 0.46 mg/dL (creatinine‐based estimated glomerular filtration rate [eGFR] 114 mL/min/1.73 m2), while serum cystatin C was 0.95 mg/L (cystatin C‐based eGFR 83.2 mL/min/1.73 m2). However, laboratory findings revealed proximal tubular dysfunction, characterized by a urine protein‐to‐creatinine ratio of 1.1 g/g and markedly elevated urinary β2‐microglobulin (>4 mg/L), associated with phosphaturia, hypercalciuria, and metabolic acidosis (serum bicarbonate 15.8 mmol/L) requiring oral bicarbonate supplementation, in the absence of glycosuria. Fractional excretion of phosphate and uric acid was increased, further supporting proximal tubular impairment. Renal ultrasonography showed normal morphology. Overall, these findings were consistent with a Fanconi‐like proximal tubular dysfunction. Serum 25‐hydroxyvitamin D was 62 ng/mL during supplementation. The patient underwent living donor LT with prompt normalization of cholestatic parameters. Following transplantation, renal tubular abnormalities improved rapidly. Urinary β2‐microglobulin normalized within the early post‐transplant period (0.017 mg/L at 2 weeks, <0.008 mg/L at 3 months), and proteinuria progressively decreased (0.2 g/g at 2 weeks, 0.15 g/g at 3 months). Post‐transplant cystatin C measurements were unavailable. Serum bile acid levels decreased from 255 µmol/L pre‐transplant to 10 µmol/L post‐transplantation, paralleling the improvement in renal tubular parameters. These findings support a reversible mechanism of tubular dysfunction related to severe and prolonged cholestasis and high circulating bile acid levels in the pre‐transplant setting. Renal tubular parameters before and after transplantation are summarized in Table 1. Table 1Renal tubular parameters before and after liver transplantation.ParameterPre‐transplantEarly post‐transplantLate post‐transplantReference rangeSerum creatinine (mg/dL)0.460.240.410.3–0.7Creatinine‐based eGFR (mL/min/1.73 m2)114>150128>90Cystatin C, mg/L0.95NANA0.88–1.06a Cystatin C‐based eGFR, mL/min/1.73 m2 83.2NANA>90Urine protein/creatinine ratio (g/g)1.10.20.15<0.2Urinary β2‐microglobulin (mg/L)>40.017<0.008<0.3a Serum bicarbonate (mmol/L)15.818.22222–26Fractional excretion of phosphate (%)18.892.7<10–15a Fractional excretion of uric acid (%)30.35.93.55–10a Note: Early post‐transplant refers to 2 weeks and late post‐transplant to 3 months after transplantation.Abbreviations: eGFR, estimated glomerular filtration rate; NA, not applicable.aReference ranges for urinary β2‐microglobulin, serum cystatin C and fractional excretion indices are age‐dependent and may vary according to laboratory methods. Renal tubular parameters before and after liver transplantation. Note: Early post‐transplant refers to 2 weeks and late post‐transplant to 3 months after transplantation. Abbreviations: eGFR, estimated glomerular filtration rate; NA, not applicable. Reference ranges for urinary β2‐microglobulin, serum cystatin C and fractional excretion indices are age‐dependent and may vary according to laboratory methods. During the post‐transplant course, after resolution of tubular abnormalities, the patient developed protein‐losing enteropathy, confirmed by scintigraphy, which improved with treatment using an ileal bile acid transporter inhibitor. 4 This sequence further supports persistent extrahepatic epithelial dysfunction despite correction of hepatic cholestasis. Genetic analysis identified a homozygous in‐frame deletion in ATP8B1 (c.1587_1589delCTT; p.Phe529del), consistent with PFIC1. 3 A genetic panel for inherited tubulopathies was negative, supporting a secondary etiology of the tubular dysfunction. DISCUSSION Renal involvement has not traditionally been considered a feature of PFIC1, and data on tubular dysfunction are limited. In this case, a clear pattern of proximal tubular dysfunction was observed before LT, including β2‐microglobulinuria, proteinuria, phosphaturia, hypercalciuria, and metabolic acidosis. Although the lower cystatin C‐based eGFR suggested that creatinine may have modestly overestimated glomerular filtration, the renal phenotype remained predominantly tubular. Importantly, these abnormalities showed rapid and marked improvement after LT, supporting a functional and reversible process. Reports of proximal tubular dysfunction in the setting of severe PFIC1‐related cholestasis are extremely rare, and reversible Fanconi‐like dysfunction normalizing after LT appears exceptional. This improvement was accompanied by a substantial decrease in circulating bile acids (from 255 to 10 µmol/L), further supporting an association between bile acid burden and tubular dysfunction. We hypothesize that prolonged exposure to markedly elevated bile acid levels may have played a central role in the development of tubular injury in this patient. The advanced and longstanding cholestatic state may have increased susceptibility to bile acid‐mediated epithelial damage, potentially in the context of underlying ATP8B1‐related epithelial vulnerability. The underlying mechanisms are likely multifactorial, but appear to be largely driven by the systemic consequences of severe and prolonged cholestasis with sustained exposure to high circulating bile acid levels. 5 Elevated circulating bile acids can directly injure epithelial cells by altering membrane integrity, impairing transporter function, and inducing oxidative and metabolic stress. In the kidney, severe cholestasis can lead to tubular epithelial injury and loss of function, a process described as cholemic nephropathy. 6 , 7 Experimental data further support this mechanism: In a mouse model of obstructive cholestasis, inhibition of the apical sodium‐dependent bile acid transporter reduced renal tubular injury and prevented cholemic nephropathy. 8 The rapid recovery of tubular function after LT in our patient is consistent with restoration of bile acid homeostasis and supports a bile acid‐mediated, potentially reversible mechanism. Although the patient's proximal tubular dysfunction resolved after LT, he subsequently developed protein‐losing enteropathy, a known complication of PFIC1. While tubular dysfunction appears driven by the cholestatic milieu and is therefore reversible, intestinal manifestations likely reflect the underlying ATP8B1‐related epithelial defect and may persist or emerge independently of cholestasis. In this context, treatment with the ileal bile acid transporter inhibitor odevixibat was associated with clinical improvement, consistent with clinical trials demonstrating the efficacy of IBAT inhibitors in PFIC. 4 Vitamin D deficiency was not supported by the normal 25‐hydroxyvitamin D level of 62 ng/mL. 9 Although rifampicin has rarely been associated with Fanconi‐like syndrome in the setting of acute tubulointerstitial nephritis, its contribution in this case appears unlikely. 10 CONCLUSION This case supports a model in which prolonged cholestasis with markedly elevated bile acid levels may act as a systemic stressor, contributing to reversible proximal tubular dysfunction. Assessment of renal tubular markers, particularly urinary β2‐microglobulin, may identify reversible complications and improve pre‐transplant evaluation in patients with severe cholestasis, although these findings should be interpreted cautiously given the single‐case nature and absence of direct mechanistic evidence. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS STATEMENT Written informed consent for publication was obtained from the patient's parents/legal guardians. According to institutional policy, formal ethical approval was not required for this single anonymized case report. REFERENCES